AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04697615 — intervention group
Intervention type: DEVICE
Intervention: Algometry
Description: The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
Study NCT01198314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunosuppression withdrawal
Description: tapering off immunosuppressant
Study NCT01198314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continue of taking immunosuppressant
Description: maintain immunosuppression
Study NCT01799603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
Study NCT01431157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal nasal oxygen
Description: Nasal oxygen at 2 l/min will be given at night
Study NCT01431157 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No nasal oxygen
Description: Patients will have no intervention for sleep apnea
Study NCT01501721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based exercise program
Study NCT01501721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Nutritional counseling aiming to reduce suggar intake
Study NCT01435720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNS01-T
Description: 0.05 mg/kg twice weekly x 6 weeks
Study NCT01435720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNS01-T
Description: 0.2 mg/kg twice weekly x 6 weeks
Study NCT01435720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNS01-T
Description: 0.375 mg/kg twice weekly x 6 weeks
Study NCT01435720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNS01-T
Description: 0.0125 mg/kg twice weekly x 6 weeks
Study NCT02939742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Betamethasone 12mg IM given every 24 hours for two doses
Study NCT02939742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Study NCT02206906 — intervention group
Intervention type: BEHAVIORAL
Intervention: Incentive intervention model
Description: All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
Study NCT01220999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).
Study NCT06506552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IMA preserving
Description: Performing left hemicolectomy, sigmoidectomy or rectal resection the IMA was preserved ligating the sigmoids arteries close to the colonic wall
Study NCT06506552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IMA sectioning
Description: Performing left emicolectomy, sigmoidectomy or rectal resection the IMA is sectioned after the origin of left colic artery.
Study NCT01263522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different training programs
Description: two different endurance programs and one strength endurance program
Study NCT01263522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control condition
Description: unchanged lifestyle
Study NCT02527694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible EMS stretcher cart
Description: The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
Study NCT02527694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical CPR
Study NCT00085189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agatolimod sodium
Description: Given SC
Study NCT00085189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00925522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy Cool Path Duo Cardiac Ablation System
Description: Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode.
Study NCT02469506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
Study NCT01825811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C (Low dose)
Description: TissueGene-C at 1.0 x 10\^6 cells mixed with fibrin-glue
Study NCT01825811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C (High dose)
Description: TissueGene-C at 3.0 x 10\^6 cells mixed with fibrin-glue
Study NCT01861158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Wisely
Description: Computer-based, online, interactive parenting intervention
Study NCT01861158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Wisely
Description: Computer-based, online, interactive parenting intervention
Study NCT01729065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Description: Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
Study NCT03961724 — intervention group
Intervention type: DEVICE
Intervention: magnetic resonance image (MRI)
Description: serum metabolomics
Study NCT01657760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
Study NCT01657760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: citalopram
Description: citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
Study NCT03071523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced lingual flap
Description: Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
Study NCT03071523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periosteal releasing incision
Description: Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
Study NCT02081976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care Group
Description: The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
Study NCT02081976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Group
Description: The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
Study NCT03989609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
Study NCT03989609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
Study NCT02589613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: tap water
Description: 300ml tap water via nasogastric tube
Study NCT02589613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 300ml tap water with 75g Glucose via nasogastric tube
Study NCT02589613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: 300ml tap water with 25g Fructose via nasogastric tube
Study NCT02570100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: Collection of blood samples and tumor specimens :~Biological collection before treatment :~* 1 tumor specimen (under echographic control)~* 4 blood collections~Biological collection during treatment :~* 1 tumor specimen after 3 cycles~* 4 blood collections after 3 and 6 cycles
Study NCT01083966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS
Study NCT02562521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
Study NCT02562521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
Study NCT02562521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
Study NCT02562521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional behavioral support
Description: Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
Study NCT01122134 — intervention group
Intervention type: DRUG
Intervention: intravenous artesunate
Description: Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
Study NCT03482999 — intervention group
Intervention type: DEVICE
Intervention: TissuGlu Surgical Adhesive
Study NCT02053506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immune-enhancing nutritional beverage
Description: Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
Study NCT02053506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics (BB-12)
Description: Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
Study NCT02053506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (for nutritional beverage and probiotic)
Description: Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
Study NCT00983294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
Study NCT00983294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
Study NCT00983294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
Study NCT03093064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
Study NCT03093064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: normal saline
Description: Normal saline, intravenous infusion
Study NCT02646098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CD34+ cell selection
Description: CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
Study NCT02588521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794
Study NCT02588521 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Vehicle
Description: Suspension vehicle without active drug
Study NCT01930188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
Study NCT01930188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
Study NCT01930188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
Study NCT01930188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
Study NCT03770897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopic Appendectomy
Description: surgical removal of inflamed cecal appendix by 3D laparoscopic procedure
Study NCT03770897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Laparoscopic Appendectomy
Description: surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
Study NCT00879827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix TM, Infanrix penta TM
Description: The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
Study NCT00879827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix TM
Description: The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
Study NCT02764320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Prophylactic Therapy Only
Description: Start of new migraine preventive therapy or adjustment of current preventive therapy without immediate discontinuation of the overused medication(s)
Study NCT02764320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discontinuation of Overused Medication
Description: Immediate discontinuation of the overused medication(s) and the start of new migraine preventive therapy or adjustment of current preventive therapy
Study NCT00986505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous lidocaine once a week
Study NCT02383797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix
Description: Vaccination against varicella in selected cartilage-hair hypoplasia patients
Study NCT03392844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beds for Kids program
Description: The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes.
Study NCT02625870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-Acid Ethyl Esters 90 Soft Capsules
Description: Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
Study NCT02625870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corn Oil
Description: Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
Study NCT01579955 — intervention group
Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Prescription of eptacog alpha at the discretion of the physician
Study NCT05303324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
Study NCT03944889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.
Study NCT03944889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delsys Trigno Galileo System
Description: This device is a wireless surface EMG device.
Study NCT03944889 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Delsys Trigno Galileo System
Description: This device is a wireless surface EMG device.
Study NCT03944889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cadwell Sierra Wave
Description: Intramuscular EMG recording machinery
Study NCT03944889 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cadwell Sierra Wave
Description: Intramuscular EMG recording machinery
Study NCT02125565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injected subcutaneous local (lidocaine) anaesthesia
Description: Trial of technique
Study NCT03944889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System
Study NCT02704689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuLIF expandable TLIF cage
Description: AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
Study NCT05093803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP
Description: Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.